Rosatom sanctions

(a) In general Upon making an affirmative determination under section 301 and not later than 15 days following such a determination, the President shall impose the sanctions described in section 317 with respect to— (1) Rosatom; (2) Rosatom subsidiaries; and (3) a foreign person that knowingly directly or indirectly engages in any significant transaction for nuclear reactor construction and related services with Rosatom. (b) Waiver The President may waive the application of sanctions for a transaction or transactions with a United States person, a foreign person, or a foreign financial institution (as the case may be) described under this section if— (1) the President determines that the transaction relates to activities necessary to the production of medical isotopes or industrial isotopes; and (2) the President certifies to the appropriate congressional committees that— (A) domestic medical isotope or industrial isotope production is insufficient to meet United States patient and industry requirements; and (B) the United States is taking measurable steps to establish medical isotope or industrial isotope supply chains that are not reliant on Rosatom or other Russian source material.

(a) In general Upon making an affirmative determination under section 301 and not later than 15 days following such a determination, the President shall impose the sanctions described in section 317 with respect to— (1) Rosatom; (2) Rosatom subsidiaries; and (3) a foreign person that knowingly directly or indirectly engages in any significant transaction for nuclear reactor construction and related services with Rosatom. (b) Waiver The President may waive the application of sanctions for a transaction or transactions with a United States person, a foreign person, or a foreign financial institution (as the case may be) described under this section if— (1) the President determines that the transaction relates to activities necessary to the production of medical isotopes or industrial isotopes; and (2) the President certifies to the appropriate congressional committees that— (A) domestic medical isotope or industrial isotope production is insufficient to meet United States patient and industry requirements; and (B) the United States is taking measurable steps to establish medical isotope or industrial isotope supply chains that are not reliant on Rosatom or other Russian source material.